Measuring ctDNA levels before radiotherapy predicted PFS and overall survival, and can help determine the patients most likely to benefit from consolidation radiotherapy vs systemic therapy.
These tests would not replace routine screening but help screen patients with no symptoms or nonspecific signs for cancers for which we could not otherwise screen, says an oncologist.
People diagnosed with clonal hematopoiesis of indeterminate potential (CHIP) or clonal cytopenia of undetermined significance (CCUS) should receive counseling, experts say.
WebMD Chief Medical Officer John Whyte, MD, MPH, speaks with Elcin Barker Ergun, CEO of the Menarini Group, in Florence, Italy, about what they believe to be a new renaissance in healthcare.